Drug-eluting stent safety: findings from preclinical studies.
After pivotal clinical trials, drug-eluting stents (DES) are now considered the standard of care for the management of acute coronary syndrome. However, late stent thrombosis has emerged as a major concern. Preclinical testing is an important regulatory process that determines the safety and efficacy of devices prior to human clinical trials. Histopathologic analysis following placement of DES has typically been performed in porcine coronary artery models to ensure safety in these devices. The recently issued consensus report from the US FDA, for the approval of DES recommends the use of the porcine model for the safety assessment of these devices in the vascular bed for which they are intended. Other models are also recommended, as vascular responses to stents are much slower in man than in animals, and no animal truly elicits the response seen in humans. The rabbit iliac artery can provide further data, especially regarding endothelialization, which is slower in the rabbit model than in the porcine model. Furthermore, inflammation is not as extensive in the rabbit and may thus be a closer model of humans than the porcine models. The FDA recognizes that it may be more appropriate to test these devices in atherosclerosis. The choice of animal model may mask the serious drawbacks of the devices; therefore, we suggest the use of both models to understand the healing following DES implantation, with emphasis on endothelialization, inflammation and neointimal formation and, whenever possible, to complement the observations in the environment of atherosclerosis.
Nakazawa
Gaku
G
CVPath Institute, Inc., 19 Firstfield Road, Gaithersburg, MD 20850, USA. gnakazawa@cvpath.org
Finn
Aloke V
AV
Ladich
Elena
E
Ribichini
Flavio
F
Coleman
Leslie
L
Kolodgie
Frank D
FD
Virmani
Renu
R
D054058:Acute Coronary Syndrome / Q000628:therapy*; D000818:Animals; D050197:Atherosclerosis / Q000150:complications; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical / Q000379:methods; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D042783:Endothelial Cells / Q000378:metabolism; D006801:Humans; D011817:Rabbits; D013045:Species Specificity; D013552:Swine; D013927:Thrombosis / Q000209:etiology; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration